Xintela AB Interim Report January – March 2026

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupFirst quarter 2026Income amounted to TSEK 443 (140).Loss before tax totalled TSEK 11,780 (loss: 10,661).Loss per share was SEK 0.02 (loss: 0.02). The Parent companyFirst quarter 2026Income amounted to TSEK 443 (140).Loss before tax totalled TSEK 10,704 (loss: 8,574). […]

Xintela reports safety results from the XSTEM clinical study in difficult-to-heal venous leg ulcers

Xintela announces that the XSTEM® treatment in the clinical Phase I/IIa study on patients with difficult-to-heal venous leg ulcers was considered safe and well tolerated and thus achieved the primary objective of the study. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela’s completed Phase I/IIa […]

Xintela AB changes Certified Adviser to Västra Hamnen Corporate Finance AB

Xintela AB announces today that the company is changing its Certified Adviser to Västra Hamnen Corporate Finance AB. Xintela AB has entered into an agreement with Västra Hamnen Corporate Finance AB regarding the role as Certified Adviser. Västra Hamnen Corporate Finance AB will assume the role of Certified Adviser on June 1, 2026. Until then, […]

Xintela AB publishes Annual Report 2025

Xintela AB (publ) announces that the company’s annual report for 2025 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela (XINT) is a publicly-traded clinical-stage biopharma company, […]

Xintela granted US patent for XSTEM treatment of difficult-to-heal wounds and skin defects

Xintela (XINT) announces today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of the company’s stem cell product XSTEM® for the treatment and regeneration of skin defects, including difficult-to-heal (chronic) wounds. The patent, US 12,599,633, issues today and protects XSTEM in the United States until 7 June […]

Xintela publication on EQSTEM treatment of horses in a preclinical osteoarthritis study awarded best basic science paper

The results from Xintela’s preclinical EQSTEM® study in horses with post-traumatic osteoarthritis (OA) has previously been published in the scientific journal Cartilage. The results show less pain and less cartilage damage after treatment with the stem cell product EQSTEM, indicating a disease modifying effect of EQSTEM. The publication has now been awarded best basic science […]

Xintela AB Year-end Report 2025

Summary of the year-end reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupForth quarter 2025Income amounted to TSEK 415 (1,090).Loss before tax totalled TSEK 17,343 (loss: 11,712).Loss per share was SEK 0.02 (loss: 0.02). Full year 2025Income amounted to TSEK 2,282 (4,215).Loss before tax totalled TSEK 50,158 (loss: 41,534).Loss per share […]

Xintelling No. 1 2026

Read Xintela´s newsletter in English here Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela (XINT) is a publicly-traded clinical-stage biopharma company, that develops cutting edge medical products in stem cell therapy and targeted cancer therapy. Xintela’s proprietary technology uses the stem cell marker integrin […]

Xintela completes clinical study with XSTEM in difficult-to-heal leg ulcers

Xintela (XINT) announces that the company’s clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers has been completed with the last follow-up visit for the last patient. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela’s Phase I/IIa clinical study in patients […]